April 2026 Research Update

This month included an early signal that asfotase alfa (an enzyme replacement therapy) might support bone healing in some people with hypophosphatasia who have delayed fracture healing. The evidence is limited to a single patient, but it adds a concrete example of healing that could be difficult to achieve with usual supportive care alone. Because it is one case, it cannot show what will happen for most patients, but it helps clarify what researchers are watching for: whether replacing alkaline phosphatase activity can translate into visible bone repair on imaging. [1]

In a 16-year-old girl with genetically confirmed hypophosphatasia and slow healing of a fifth metatarsal fracture, imaging after starting asfotase alfa showed complete fracture consolidation by 13 weeks. The report also measured bone density in the fracture gap, which increased by 36% and returned to the average level for that bone region. This supports the idea that enzyme replacement can be linked to measurable changes in bone repair in at least some pediatric situations. [1]

For patients and caregivers, this report mainly adds understanding rather than changing anything right now, because it describes only one teenager. It suggests a possible connection between asfotase alfa and improved fracture healing on scans when healing has been delayed, which may be most relevant for families who have faced stress fractures or slow-to-heal fractures. What remains uncertain is how often this happens, which types of fractures respond, and whether similar results would be seen across different ages and forms of hypophosphatasia. [1]

These studies showed that hypophosphatasia genetics can help explain very different real-life situations, from severe infant disease to subtle adult disease found through lab testing. Across the reports, ALPL gene changes were central, but the lived experience differed a lot, which fits with the idea that hypophosphatasia can vary widely even within families. This month added examples of how genetic results were linked either to severe early skeletal problems or to a diagnosis made despite few typical symptoms. [2] [3]

In monozygotic infant twins with hypophosphatasia, laboratory testing of one ALPL variant (c.299C>T) suggested it interfered with enzyme function in a dominant-negative way, leading to low alkaline phosphatase activity. The clinical course included skeletal dysplasia and high calcium levels, and one twin died from pneumonia before 12 months. The authors also compared similar variants in a database and reported differences between early- and late-onset cases in how strongly this dominant-negative effect showed up, linking variant behavior in the lab to differences seen across ages of onset. [2]

In an adult with persistently low alkaline phosphatase for over a decade, genetic testing confirmed autosomal dominant hypophosphatasia even though typical bone or dental symptoms were not present. The patient also had Addison's disease and primary hypothyroidism, and the diagnosis prompted family genetic discussions such as cascade testing. This illustrates that, for some people, hypophosphatasia may first appear as an unexplained lab pattern rather than obvious fractures or tooth problems. [3]

For patients, these reports reinforce that hypophosphatasia can look very different from one person to another, even when the condition is confirmed genetically. The infant twin report may matter later because it connects a specific kind of ALPL variant effect in the lab to severe early disease patterns, but it is still early research and based on one family. The adult report may matter now in awareness terms because it shows that long-standing low alkaline phosphatase can be a clue to hypophosphatasia even when symptoms are not typical, while also highlighting that families may consider genetic testing discussions once a diagnosis is confirmed. [2] [3]